logo
Share SHARE
FONT-SIZE Plus   Neg

Sanofi To Buy Pluromed - Quick Facts

Sanofi (SNY,SNYNF.PK) and Pluromed Inc. announced that they have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts.

As part of the agreement, Sanofi will commercialize Pluromed's LeGoo, a highly innovative FDA approved and CE marked gel for temporary endovascular occlusion of blood vessels during surgical procedures.

Alison Lawton, senior vice president and general manager, Sanofi Biosurgery, commented, "The acquisition of Pluromed underscores Sanofi's commitment to strengthen its Biosurgery portfolio. LeGoo is a breakthrough technology with the potential to change the paradigm of vascular and cardiovascular surgical procedures, by providing fast, temporary control of blood flow while avoiding vessel trauma associated with standard of care."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Sanofi SA were gaining around 2 percent in the early morning trading in Paris after the French drug giant reported significantly higher profit in its first quarter, benefited by 4.4 billion euros gains from the disposal of its Merial animal healthcare unit and higher sales. For fiscal 2017, Sanofi said it continues to expect Business earnings per share to be stable to negative 3 percent. Shares of UBS Group AG were gaining around 4 percent in the early morning trading after the Swiss banking giant reported Friday significantly higher profit in its first quarter, despite weakness in net interest income. The company also proposed a dividend. Looking ahead, UBS said it is well positioned to mitigate various market challenges... Alphabet Inc. (GOOG, GOOGL), the parent company of Google, Thursday reported an increase in profit for the first quarter, driven largely revenue growth in search and advertising. Alphabet's first-quarter profit rose to $5.43 billion or $7.73 per share from $4.21 billion or $6.02 per share last year. On...
comments powered by Disqus
Follow RTT